Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine

When astronauts board a rocket for the International Space Station, or soldiers deploy to remote battlefields, they carry medical kits designed for a temperature-controlled pharmacy shelf. The problem? No one actually knows if those life-saving drugs still work once they hit the gauntlet of cosmic radiation or extreme terrestrial environments.

Enter Astraea Technologies, an Australian deep tech startup on a mission to ensure that the medicine we rely on in extreme conditions doesn’t turn into a cabinet of expensive placebos. Led by CEO Brooke Mills and CTO Gordon Carroll, the company is currently seeking $5 million in seed funding to commercialise its proprietary HIRO-LAB platform.

While the aerospace industry has spent decades fortifying hardware against the rigours of space, the healthcare and medicine used in space have simply been transported from the terrestrial healthcare system. On Earth, we are shielded by the atmosphere and these products are designed as such. But in space, radiation acts like a “bowling ball” that collides with human DNA, and this effect has not been thoroughly studied to determine its impact on human healthcare products. Space missions to date have relied on frequent resupply missions, but for future planned long-duration missions, this reliance cannot continue.. 

Astraea’s solution is Astraea Drift, a full-spectrum degradation-profiling service enabled by its Heavy Ionising Radiation Observatory Laboratory (HIRO-LAB) platform. HIRO-LAB is a device roughly the size of a sandwich that provides real-time, continuous monitoring of samples under radiation bombardment. Unlike traditional labs that test samples before and after exposure, missing the potential complex “self-healing” or degradation spikes that occur during the journey, HIRO-LAB tracks the full degradation profile of an enclosed sample. 

The company isn’t just theorising; it has a packed flight manifest. Astraea has already secured:

“We’re not coming for the big established labs,” explains Gordon, a neuroscientist turned space technologist. “We fit a niche they haven’t considered. We can take an existing pharmaceutical and say, ‘This is its full journey, and here is how we can stop it from degrading.'”